anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An initial pre-anesthetic evaluation and physical examination will be performed by an attending anesthesiologist, and an eye exam will be performed by an attending ophthalmologist to determine suitability for inclusion according to the above criteria. Ideally the eye exam will take place immediately prior to conduction of the study. However, logistical restraints may require that the eye exam take place at a separate time/date prior to conduction of the study. IOPs will be measured by the attending ophthalmologist (B.E.) who will be blinded to the actual readings of the Tonopen by means of a small screen, and a single trained observer (E.F.) will record observations from the Tonopen. The nitrous oxide sedation will be managed by the attending anesthesiologist (K.L.). All patients will be monitored throughout using standardized monitoring (continuous EKG, non-invasive BP, and continuous pulse oximetry).
OBJECTIVE: To investigate cortical microstructural measures from diffusion MRI as "neurodegeneration" markers that could improve prognostic accuracy in mild cognitive impairment (MCI).
METHODS: The prognostic power of Amyloid/Tau/Neurodegeneration (ATN) biomarkers to predict progression from MCI to AD or non-AD dementia was investigated. Ninety patients underwent clinical evaluation (follow-up interval 32 ± 18 months), lumbar puncture, and MRI. Participants were grouped by clinical stage and cerebrospinal fluid Amyloid and Tau status. T1-structural and diffusion MRI scans were analyzed to calculate diffusion metrics related to cortical columnar structure (AngleR, ParlPD, PerpPD+), cortical mean diffusivity, and fractional anisotropy. Statistical tests were corrected for multiple comparisons. Prognostic power was assessed using receiver operating characteristic (ROC) analysis and related indices.
RESULTS: A progressive increase of whole-brain cortical diffusion values was observed along the AD continuum, with all A+ groups showing significantly higher AngleR than A-T-. Investigating clinical progression to dementia, the AT biomarkers together showed good positive predictive value (with 90.91% of MCI A+T+ converting to dementia) but poor negative predictive value (with 40% of MCI A-T- progressing to a mix of AD and non-AD dementias). Adding whole-brain AngleR as an N marker, produced good differentiation between stable and converting MCI A-T- patients (0.8 area under ROC curve) and substantially improved negative predictive value (+21.25%).
INTERPRETATION: Results support the clinical utility of cortical microstructure to aid prognosis, especially in A-T- patients. Further work will investigate other complexities of the real-world clinical setting, including A-T+ groups. Diffusion MRI measures of neurodegeneration may complement fluid AT markers to support clinical decision-making.
From 2011 to 2017, the investigators consecutively enrolled the pregnant women with chronic hepatitis B infection who were less than 28 weeks pregnant and not treated with nucleos(t)ide analogues during pregnancy. The investigators recommended those pregnant women with HBV DNA \> 2\*10\^6 IU/ml to receive nucleos(t)ide analogues from 28 weeks of pregnancy to delivery. Patients who agreed the antiviral treatment would assigned to the treatment group and those who declined it were assigned to the control group with high HBV DNA level. Meanwhile, those pregnant women with HBV DNA \< 2\*10\^6 IU/ml was assigned as the control group with low HBV DNA level. All infants would be instructed to receive hepatitis B vaccine and hepatitis B virus immunoglobulin within 24 hours after birth, defined as the standard immunoprophylaxis strategy and encouraged to receive immunoprophylaxis within 2 hours after birth, defined as the aggressive immunoprophylaxis strategy. Umbilical cord blood were collected to determine the HBV serological markers and HBV DNA level. Children were followed every three to four years until December 2018.
A four-year-old spayed female Shiba Inu dog weighing 6.1 kg presented with ascites. Cor triatriatum dexter (CTD) without any other concurrent cardiovascular anomalies was diagnosed using echocardiography. The ostium of the abnormal membrane dividing the right atrium into two abnormal chambers was surgically excised under cardiopulmonary bypass. All clinical abnormalities were resolved after surgery. However, seven months later, ascites and CTD recurred. A balloon-expandable stent was placed at the site of recurrence, which improved caudal venous return to the right ventricle. After the second procedure, ascites were resolved, and the dog remained asymptomatic for 18 months without complications. There are previous reports of successful surgical resection of the CTD and of stenting in recurrent CTD following balloon dilation in dogs. However, to the authors' knowledge, no previous reports have described recurrent CTD in dogs after surgical resection of the CTD. In this case, as with recurrent CTD following balloon dilation, stent placement at the site of the CTD can be a viable treatment option when the abnormal membrane recurs.
Subretinal fibrosis permanently impairs the vision of patients with neovascular age-related macular degeneration. Despite emerging evidence revealing the association between disturbed metabolism in retinal pigment epithelium (RPE) and subretinal fibrosis, the underlying mechanism remains unclear. In the present study, single-cell RNA sequencing revealed, prior to subretinal fibrosis, genes in mitochondrial fatty acid oxidation are downregulated in the RPE lacking very low-density lipoprotein receptor (VLDLR), especially the rate-limiting enzyme carnitine palmitoyltransferase 1A (CPT1A). We found that overexpression of CPT1A in the RPE of Vldlr-/- mice suppresses epithelial-to-mesenchymal transition and fibrosis. Mechanistically, TGFβ2 induces fibrosis by activating a Warburg-like effect, i.e. increased glycolysis and decreased mitochondrial respiration through ERK-dependent CPT1A degradation. Moreover, VLDLR blocks the formation of the TGFβ receptor I/II complex by interacting with unglycosylated TGFβ receptor II. In conclusion, VLDLR suppresses fibrosis by attenuating TGFβ2-induced metabolic reprogramming, and CPT1A is a potential target for treating subretinal fibrosis.
PURPOSE: To obtain a prepack agent being applied to skin before use of a peel off type pack so as to improve the feeling in use of the pack, containing a cationic surfactant. CONSTITUTION: This prepack agent contains 0.01-10wt.% of a cationic surfactant of formula I, formula II or formula III (R<1> to R<6> are each an alkyl, an alkenyl or an aryl; X is a halogen or monosulfuric ester residue) (e.g. distearyldimethylammonium chloride). The agent contains further 0.01-10wt.% of a water-soluble pdlymer (e.g. hydroxyethyl cellulose) and 0.1-70wt.% of an oil agent (e.g. amino-modified silicone). The prepack agent is applied to skin before use of a peel off type pack agent and used to prevent peel residue in peeling and to alleviate pain in peeling without drying the peel off type pack agent and without lowering a coating film forming rate.
The prevalence of obesity and associated morbidity among Canadian adults is already high and increasing. Prevalence estimates for overweight determined from measured height and weight now exceeds 62 % in Canadian adults1; approximately 15.5 million Canadian adults are now overweight and obese1. Obesity is associated with a wide range of health outcomes from co-morbidities including type 2 diabetes, cardiovascular disease and certain cancers, to psychiatric disorders such as depression1. Direct costs attributed to obesity in Canada range from 4.6 to 7.1 billion dollars annually1. Despite agreement concerning the urgent need to address the obesity problem; few strategies have been successful on a wide scale basis. Past efforts to achieve and sustain weight loss have not been particularly successful. We3 and others4 have repeatedly demonstrated in randomized controlled trials that most adults are not able to sustain the major changes in behaviour that are required to maintain weight loss long term. Thus, although it is an admirable goal to substantially reduce the number of overweight or obese Canadians, this goal may be totally out of reach in the short term. The question then is what can be done to address the obesity problem now? We propose that a reasonable start point in addressing the obesity problem is to develop behavioural goals for prevention of weight gain. This strategy can at least keep the problem from getting worse and at best, can reduce obesity rates over time.
Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT and blood sample collection throughout the trial.
The study population will include Chinese adult men and women, over the age of 18 years. All subjects will be recruited at Fudan University. Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
The present invention relates to a taiyi liver protection capsule and a preparation method thereof, and the taiyi liver protection capsule belongs to a pure Chinese herb compound capsule preparation for treating hepatitis B and hepatitis B virus infection. A prescription is prepared from heterophylly falsestarwort root, raw milkvetch root, large-flowered purslane, raw rhubarb, oldenlandia, red sage root, hawthorn fruit, baical skullcap root, bupleurum root, twotoothed achyranthes root, rhizoma, black ant and ganoderma. The rhubarb, the ganoderma, the rhizoma and the black ants in the prescription are pulverized into fine powder; the rest medicinal ingredients are decocted thrice by adding water; decoction liquid is merged and filtered; filter liquid is concentrated into ointment; the ointment is mixed with the fine powder and manufactured into granules; the present invention is obtained by that the granules is dried, pulverized and encapsulated. Content in the capsule is brownish yellow powder with fragrance and mildly bitter flavor, and 0.45 gram of the brownish yellow powder is filled in each capsule. The present invention is orally admitted thrice a day, and 4 to 6 capsules are swallowed with warm water after one hour after meal each time. Drinking is avoided during the period of taking medicine. The present invention is suitable for treating antiviral immunity regulation and control of PCR positive patients with dasanyang and xiaosanyang which are infected by the hepatitis B viruses. The total effective rate of the conversion of hepatitis B virus carriers is 78.7%, and the present invention has a favorable effect on treating ASC.
PROBLEM TO BE SOLVED: To obtain a highly safe skin roughness-improving preparation for external use, having excellent effects for improving and preventing various kinds of skin diseases, skin roughness, rough skins, etc., by compounding the extract of Sophora flavescens Aiton. SOLUTION: This preparation for external use for improving skin roughness contains the solvent extract of a perennial plant, Sophora flavescens Aiton, as an active ingredient in an amount of 0.0005-20wt.%, preferably 0.001-10wt.%, based on the whole amount of the preparation for external use as a dry product. The extract is especially obtained by immersing or thermally refluxing the roots of the Sophora flavescens Aiton in a solvent (e.g. 1,3-butyleneglycol), filtering and subsequently concentrating the filtrate. Ointments, creams, milky lotions, lotions, packs, bath articles, etc., can be prepared by conventional methods. The skin roughness-improving preparation for external use especially exhibits an inhibiting activity against serine protease as a protease-inhibiting agent.  The preparation is effective for skin roughness caused by various kinds of skin diseases such as contact dermatitis and psoriasis, the skin roughness of healthy person, rough skins, etc.
Anti-coagulant material is prepared from the blood-sucking insect Rhodnius prolixus stal. by centrifuging a suspension in a saline medium of the homogenised insect, to remove tissue debris, treating the supernatant with a protein precipitant, extracting the resulting precipitate with a saline medium, and recovering the saline extract containing the required material.  The preferred starting material is the excised gut of the insect; the protein precipitant may be acetone, methyl ethyl ketone, or other organic liquids, or inorganic salts may be used.  The saline extract may be concentrated, if required to dryness, in a vacuum dessicator at room temperature.  A further purification by heating the extract to 80 DEG C. for ten minutes, to precipitate unwanted protein, may be performed before drying.  The product has anti-thrombin activity similar to heparin, and a molecular weight of 100,000 to 200,000.
PURPOSE OF REVIEW: The purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation.
RECENT FINDINGS: There is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort. Ongoing studies are investigating the role of treatment-free remission in children. Chronic phase CML in children is managed with lifelong TKI therapy; however, evidence of deeper remissions sustained with second-generation TKIs may permit shorter treatment courses. Use of more specific TKIs may mitigate some of the side effects specific to the pediatric cohort. Children with advanced phase CML should achieve a complete hematologic remission with use of a second-generation TKI prior to transplant to achieve the best outcome.
Astaxanthin will be administered in a dosage of 12 mg/day orally by one soft gel capsule per day. the capsule consist of natural Astaxanthin and olive oil.
BACKGROUND: Coronary artery bypass grafting (CABG) is often performed with hypothermic cardiopulmonary bypass (CPB) to reduce metabolic demands and protect the myocardium. However, hypothermia can increase bleeding risks and other complications.
METHODS: This is a prospective, multi-center, randomized controlled trial. From September 2023 to December 2024, a total of 336 eligible patients planning to undergo on-pump CABG will be enrolled. All participants will be randomly divided into mild hypothermia CPB group (target oxygenator arterial outlet blood temperature at 32-33℃) or normothermia CPB group (target oxygenator arterial outlet blood temperature at 35-36℃). The primary endpoint is Universal Definition of Perioperative Bleeding (UDPB) class 2-4. Secondary endpoints are class of UDPB, levels of coagulation and inflammatory factors, in-hospital mortality, perioperative related complications, ICU length of stay, and hospital length of stay.
DISCUSSION: This clinical trial aims to compare the effects of different target temperature during CPB on postoperative bleeding and to explore optimal temperature strategy to provide new clinical evidence.
TRIAL REGISTRATION: Chictr.org.cn : ChiCTR2300075405. The trial was prospectively registered on 4 September 2023.
Previous studies have highlighted the protective effects of pyruvate kinase M2 (PKM2) overexpression in septic cardiomyopathy. In our study, we utilized cardiomyocyte-specific PKM2 knockout mice to further investigate the role of PKM2 in attenuating LPS-induced myocardial dysfunction, focusing on mitochondrial biogenesis and prohibitin 2 (PHB2). Our findings confirmed that the deletion of PKM2 in cardiomyocytes significantly exacerbated LPS-induced myocardial dysfunction, as evidenced by impaired contractile function and relaxation. Additionally, the deletion of PKM2 intensified LPS-induced myocardial inflammation. At the molecular level, LPS triggered mitochondrial dysfunction, characterized by reduced ATP production, compromised mitochondrial respiratory complex I/III activities, and increased ROS production. Intriguingly, the absence of PKM2 further worsened LPS-induced mitochondrial damage. Our molecular investigations revealed that LPS disrupted mitochondrial biogenesis in cardiomyocytes, a disruption that was exacerbated by the absence of PKM2. Given that PHB2 is known as a downstream effector of PKM2, we employed PHB2 adenovirus to restore PHB2 levels. The overexpression of PHB2 normalized mitochondrial biogenesis, restored mitochondrial integrity, and promoted mitochondrial function. Overall, our results underscore the critical role of PKM2 in regulating the progression of septic cardiomyopathy. PKM2 deficiency impeded mitochondrial biogenesis, leading to compromised mitochondrial integrity, increased myocardial inflammation, and impaired cardiac function. The overexpression of PHB2 mitigated the deleterious effects of PKM2 deletion. This discovery offers a novel insight into the molecular mechanisms underlying septic cardiomyopathy and suggests potential therapeutic targets for intervention.
Unless specific compatibility data are available, idarubicin hydrochloride should not be mixed with other drugs. Precipitation occurs with heparin. Prolonged contact with any solution of an alkaline pH will result in degradation of the drug.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and containers permit.

Handling and Disposal: Procedures for handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1-8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
Dose chosen for Part 2 was twice a day dosing. For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, and in the evening.
A directed evolution process for rapid and facilitated production from a progenitor polynucleotide template, of a library of mutagenized progeny polynucleotides wherein each of the 20 naturally encoded amino acids is encoded at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate N,N,G/T sequence. Also, a method of non-stochastically producing a library of chimeric nucleic acid molecules having an overall assembly order that is chosen by design. Accordingly, a set of progenitor templates, such as genes (e.g. a family of esterase genes) or genes pathways (e.g. encoding antibiotics) can be shuffled to generate a sizable library of distinct progeny polynucleotide molecules (e.g. 10 100 ) and correspondingly encoded polypeptides.
Donor priming and apheresis will include filgrastim 8 mcg/kg subcutaneously twice daily for 4 days prior to stem cell collection and continuing until pheresis is completed. Alternative mobilization strategies may be employed at the investigator's discretion.
The present invention relates to a thermosensitive composition preventing tissue adhesion and a method for preparing the same. More specifically, the present invention relates to a thermosensitive composition preventing tissue adhesion which further contains a drug selectively inhibiting inflammatory response and a method for preparing the composition. The composition is fabricated through a chemical reaction by adding a cross-linking agent to an aqueous solution. The aqueous solution contains: a block copolymer containing a polyethyleneoxide block having the ability to suppress tissue adhesion, and a polymer with 10,000 to 1,000,000 g/mol of molecular weight which can be mixed with the copolymer. Also, the composition is characterized in that the differences of viscosity, absorbance of visible region, and stability between the upper and lower liquid layers are within 10% when centrifuging the composition. In addition, the method for preparing the composition enhances cross-linking homogenization and viscosity stability through simultaneous spraying and stirring methods without a reaction retardant. According to the present invention, floating debris on a fiber which is caused by uneven cross-linking can be not only prevented, but cross-linking homogenization and viscosity stabilization can also be enhanced. Therefore, the composition can be uniformly applied to a wound on a human body and has high stability and excellent effect of preventing tissue adhesion.
Bacterial contamination as a result of suture contamination may be associated with rotator cuff retear or impaired tendon healing after rotator cuff repair. This represents a potential new area of focus and intervention. Despite an array of rotator cuff repair techniques, from varying suture configurations and double-row repairs to biologic adjuncts and patches, a substantial proportion of repairs do not heal or go on to retear. Decades of research have been dedicated to identifying risk factors for these failures and mitigating their influence. Yet, as we transitioned from open to arthroscopic repair, we became less concerned with regard to overt infection, which is rare using arthroscopic techniques. Now, we must take precautions to prevent occult bacterial contamination. The importance of stringent aseptic practices and tailored prophylactic measures, even in seemingly low-risk arthroscopy cases, requires attention, and similarly, with increasing numbers of shoulder injections, antisepsis around the shoulder must be practiced in all cases.
<P>PROBLEM TO BE SOLVED: To provide a transgenic non-human animal producing heterologous antibodies and a method for producing human sequence antibodies which bind to human antigens with substantial affinity.  <P>SOLUTION: A cell containing at least one artificial gene encoding at least a part of immunoglobulin polypeptides is provided. The cell produces a detectable amount of immunoglobulin bonding to a predetermined human antigen. The immunoglobulin polypeptides substantially have the same sequence as that of the immunoglobulin polypeptides secreted by hybridomas obtained from transgenic mice. The mouse includes a pair of homozygoses of functionally destroyed endogenous heavy chain allele, a pair of homozygotes of functionally destroyed endogenous light chain allele, at least one copy of a human immunoglobulin light chain transgene and at least one copy of a human immunoglobulin heavy chain transgene. The immunoglobulin binds to the human antigen with at least a 1.1×109M-1 affinity constant (Ka) in order to bind to the human antigen.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PURPOSE:A remedy for hemorrhoids containing an organic solvent-soluble fraction of crude drug of zingiberaceous plant as an active ingredient. CONSTITUTION:1pts.wt. crude drug of zingiberaceous plant (e.g., ginger, Zingiberis Siccatum Rhizoma, Wild Siamese Cardamoms, Alphiniae Officinarum Rhizoma, etc.) is extracted with >=3pts.wt. organic solvent (e.g., ethanol, acetone, ethyl acetate, etc.) at 25-45 deg.C for 12-24hr. The same operation is repeated for two or three times, to give an organic solvent-soluble fraction. 0.01- 0.5wt% calculated as dry weight of the fraction is added to pharmaceutical preparation, to give a remedy for hemorrhoids. The remedy may be blended with a drug having analgesic action, antipruritic action, antimicrobial action, anti-inflammatory action, local hemostatic action, etc. besides the soluble fraction. A supposotory, ointment, oily base or spray may be used in administration.
When a person with celiac disease is exposed to gluten, their immune system attacks their bowel and causes abdominal pain, bloating, and diarrhea. This process takes 24-72 hours to occur. Some people without celiac disease develop similar symptoms when they eat gluten or wheat. Doctors and scientists do not know what causes this sensitivity to gluten. People with celiac disease and non-celiac gluten sensitivity report symptoms within hours of being exposed to gluten. This study evaluates why this occurs by looking at changes in blood, urine, stool, and the bowel after being given gluten.